All In Biotech

Drug Trial Radar · NCT06173869

A Randomised Trial Comparing the Ovarian Response of a Starting Dose of Either 10 μg or 15 μg Follitropin Delta (FE 999049) to a Starting Dose of Either 150 IU or 225 IU Follitropin Alfa (GONAL-F) in Conventional Regimens in China

A Randomised, Controlled, Assessor-blind, Parallel Groups, Multicentre Trial Comparing the Ovarian Response of a Starting Dose of Either 10 μg or 15 μg Follitropin Delta (FE 999049) to a Starting Dose of Either 150 IU or 225 IU Follitropin Alfa (GONAL-F) in Conventional Regimens in Controlled Ovarian Stimulation in Women Undergoing an Assisted Reproductive Technology Programme in China

Last checked: Nov 19, 2026Latest source record: Feb 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 301 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

301

Actual

Start

Mar 29, 2024

Primary completion

May 31, 2025

Study completion May 31, 2025

Sponsor

Lead sponsor
Ferring PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Dec 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 20 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 3b clinical trial with follitropin delta (FE 999049) and Gonal-F. The trial is a randomised, controlled, assessor-blind, parallel groups, multicentre trial comparing the ovarian response of a starting dose of either 10mg or 15 mg follitropin delta to a starting dose of either 150 IU or 225 IU Gonal-F in a long GnRH agonist protocol in women undergoing an assisted reproductive technology programme in China.

Conditions

  • Infertility, Female

Interventions

  • FE 999049Drug

    FE 999049 was administered as single daily subcutaneous injections at a starting dose of either 10 or 15 µg daily that was fixed for the first five stimulation days. Based on ovarian response, the dose could be increased or decreased by 5 µg, with dose adjustments implemented not more frequently than once every 2 days per investigator's judgement. The minimum daily dose was 5 µg, and the maximum daily dose was 20 µg. Participants could be treated for a maximum of 20 days.

  • GONAL-FDrug

    GONAL-F was administered as single daily subcutaneous injections at a starting dose of either 150 or 225 IU daily that was fixed for the first five stimulation days. Based on ovarian response, the dose could be increased or decreased by 75 IU, with dose adjustments implemented not more frequently than once every 2 days per investigator's judgement. The minimum daily dose was 75 IU, and the maximum daily dose was 300 IU. Participants could be treated for a maximum of 20 days. Coasting was not allowed.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Oocytes RetrievedTime frame: On day of oocyte retrieval (up to 22 days after start of stimulation)

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Ferring Investigational Site

    Shushan, Anhui, China

  • Ferring Investigational Site

    Yuzhong, Chongqing Municipality, China

  • Ferring Investigational Site

    Guangzhou, Guandong, China

  • Ferring Investigational Site

    Guangzhou, Guangdong, China

  • Ferring Investigational Site

    Zhengzhou, Henan, China

  • Ferring Investigational Site

    Nanchang, Jiangxi, China

  • Ferring Investigational Site

    Shengyang, Liaoling, China

  • Ferring Investigational Site

    Shanghai, Shanghai Municipality, China

  • Ferring Investigational Site

    Chengdu, Sichuang, China

  • Ferring Investigational Site

    Tianjin, Tianjin Municipality, China

  • Ferring Investigational Site

    Xiaobailou, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.